Impax Laboratories (IPXL) Stock Price, News & Analysis

Company Overview

Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generics and Specialty segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.

Key Stats

• Today's Range: $17.40 to $18.95
• 50-Day Range: $18.30 to $18.30
• 52-Week Range: $13.05 to $25.70
• Volume: 3.04 million shs
• Average Volume: 945,265 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

IPXL Stock Analysis - Frequently Asked Questions

How were Impax Laboratories' earnings last quarter?

Impax Laboratories, Inc. (NASDAQ:IPXL) released its earnings results on Thursday, November, 9th. The specialty pharmaceutical company reported $0.23 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.20 by $0.03. Impax Laboratories's revenue for the quarter was down 9.4% compared to the same quarter last year.

What other stocks do shareholders of Impax Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Impax Laboratories investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet (CLMT), NovoCure (NVCR), Two Harbors Investments (TWO), BlackRock Capital Investment (BKCC) and Summit Midstream Partners (SMLP).

Company Calendar

• Last Earnings: 11/09/2017
• Today: 10/10/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:IPXL
• CIK: 1003642
• Web: www.impaxlabs.com
• Phone: (908) 947-3120
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Optionable
• Beta: N/A